Exclusive Summary

• - Patent barriers have expired and no originator injectable exists ex-China, enabling broad FTO and a distribution-led go-to-market in countries allowing herbal injectables.
• - Targets high-burden conditions (post-stroke symptoms, cognitive impairment, PAD) with hundreds of millions of patients, ensuring steady inpatient/outpatient demand.
• - API complies with BP/USP/EP, aligning with international quality expectations and easing multi-country registration and hospital tenders.
• - Very limited competition for injectable ginkgo in US/EU/Japan; in receptive markets, first-mover and channel differentiation are achievable.
• - Botanical raw material and small-volume injectable manufacturing keep COGS low, allowing clear price advantage versus patented neuroprotective injectables.